Servier will be responsible for development and global commercialisation of the therapy for several indications.

Black Diamond Therapeutics has found a partner for its deprioritized solid tumor candidate. Five months after cutting support ...

The partnership underscores Servier’s commitment to developing targeted therapies that address unmet medical needs in oncology Servier will ...

Black Diamond said Servier will develop and commercialize BDTX-4933, a small molecule designed by the Cambridge, Mass., company to address unmet medical needs in RAF/RAS-mutant solid tumors.

A marketing expert reacts to an image of see-through Black Diamond American cheese, claiming it could be a result of ...

Servier announces a strategic worldwide licensing agreement for Black Diamond Therapeutics' BDTX-4933 for solid tumors for an ...

Black Diamond Therapeutics presents a compelling investment opportunity with strong potential, balanced by inherent biotech ...

Stifel Nicolaus analyst Bradley Canino maintained a Buy rating on Black Diamond Therapeutics (BDTX – Research Report) today and set a price ...

Shares of Black Diamond Therapeutics, Inc. (BDTX) jumped around 21% as of Wednesday noon after the company announced it had ...

Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) had its price objective upped by equities researchers at HC Wainwright from $11.00 to $12.00 in a note issued to investors on ...

Wedbush restated their outperform rating on shares of Black Diamond Therapeutics (NASDAQ:BDTX – Free Report) in a research ...